The biggest threat to provenge in the next two years is prostvac by Novartis which recently filled its patient rolls. I suspect the survival signal will be lost if the patient subsequently put on standard of care zytiga or xtandi and prostvac will likely fail.
CAR-t hype right now is siphoning investment dollars from all biotech sectors. GVHD symptoms will likely kill many patients, but at this juncture NIH is fueling the hype that those sideeffects are treatable.
To be honest with you I have no idea what you are talking about...This is not for the lack of trying...
a bunch of other states enacted this same law.
One more inreresting fact. Assuming the 1588 number is correct, in the past 10 weeks if you throw out the thanks giving week, they have grown the scripts by 4.26% a week.
If you average the increase in prescriptions since they hit 1k scripts or more, the increase was 2.72% a week. If you take it from the week they went over 500 the prescriptions they have grown at 7.25% week on the average.
I would get out also if I were not so deep in this. 5-10% increase in scripts every month is simply not going to do it for this market...
immunotherapy stocks are skyrocketing today while dendreon is in bankruptcy. This is all because the under taker decided to pull the plug. I guarantee you JJ would have been able to do a secondary by now if that director bozo did not pull the plug on JJ and hand it over to the undertaker. The sales was growing nicely million by the time the under taker pulled the plug.
It used to be you had to have a successful phase 2 study before a stock would took off.
it was, I don't know what you are talking about.